Low-grade uterine adenosarcoma without sarcomatous overgrowth is a histologically distinct subtype of uterine sarcoma. Its management follows specific evidence-based recommendations that differ meaningfully from higher-grade or more aggressive variants.
Patients present with low-grade uterine adenosarcoma in the absence of sarcomatous overgrowth. This histological distinction drives specific recommendations regarding both the primary intervention and adjuvant management, particularly for early-stage (stage I) disease.
For localized disease, the primary approach is surgical. Recommendations for adjuvant therapies at stage I are explicitly defined — and some standard adjuvant modalities are not recommended in this specific setting. The complete structured protocol is available via the link below.
DOI: 10.1136/ijgc-2024-005823
The recommended treatment for uterine adenosarcomas is a total hysterectomy and bilateral salpingo-oophorectomy, as the majority of patients are peri-/post-menopausal.
Adjuvant endocrine therapy is not recommended for stage I uterine adenosarcoma (IV, D).
Low-grade adenosarcoma should be managed similarly to patients with LG-ESS, with endocrine therapy until disease progression unless associated with unacceptable adverse effects.
View source ↗